DBVT
DBV Technologies S.A.
NASDAQHealthcareBiotechnologyFR
Rating:C
Company Profile
CEO
Daniel Tassé
IPO Date
2014-10-22
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
FR
DBV Technologies S.A.
CEO
Daniel Tassé
IPO Date
2014-10-22
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
FR
| $4.86 |
| 14 Jan 2026 | BAKER BROS. ADVISORS LP | director | M-Exempt | Disposed | 25,005,240 | $0.00 |
| 14 Jan 2026 | BAKER BROS. ADVISORS LP | director | M-Exempt | Acquired | 2,299,656 | $0.00 |
| 14 Jan 2026 | BAKER BROS. ADVISORS LP | director | M-Exempt | Acquired | 25,005,240 | $0.00 |
| 19 Dec 2025 | EPIC Bpifrance | other: Member of 10% owner group | S-Sale | Disposed | 2,036,990 | $4.84 |
| 19 Dec 2025 | EPIC Bpifrance | other: Member of 10% owner group | S-Sale | Disposed | 40,000 | $5.28 |
| 19 Dec 2025 | EPIC Bpifrance | other: Member of 10% owner group | S-Sale | Disposed | 1,292,103 | $4.19 |
| 25 Nov 2025 | Mohideen Pharis | Chief Medical Officer | S-Sale | Disposed | 6,496 | $2.88 |
| 25 Nov 2025 | Mohideen Pharis | Chief Medical Officer | S-Sale | Disposed | 1,624 | $2.77 |